{
    "Trade/Device Name(s)": [
        "CRYOcheck FVIII Inhibitor Kit",
        "CRYOcheck Factor VIII Inhibitor Kit"
    ],
    "Submitter Information": "Precision BioLogic Inc.",
    "510(k) Number": "K183440",
    "Predicate Device Reference 510(k) Number(s)": [
        "K082205"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "GGP",
        "GGN"
    ],
    "Summary Letter Date": "December 10, 2018",
    "Summary Letter Received Date": "December 12, 2018",
    "Submission Date": "December 10, 2018",
    "Regulation Number(s)": [
        "21 CFR 864.7290",
        "21 CFR 864.5425"
    ],
    "Regulation Name(s)": [
        "Factor deficiency test",
        "Multipurpose system for in vitro coagulation studies"
    ],
    "Analyte Class(es)": [
        "coagulation",
        "hematology"
    ],
    "Analyte(s)": [
        "Factor VIII inhibitor"
    ],
    "Specimen Type(s)": [
        "Human plasma"
    ],
    "Specimen Container(s)": [
        "3.2% citrated human plasma tube"
    ],
    "Instrument(s)/Platform(s)": [
        "Siemens BCS XP analyzer"
    ],
    "Method(s)/Technology(ies)": [
        "Modified Nijmegen-Bethesda assay",
        "Chromogenic assay"
    ],
    "Methodologies": [
        "Quantitative inhibitor titer measurement"
    ],
    "Submission Type(s)": [
        "Kit",
        "Control",
        "Reagent"
    ],
    "Document Summary": "FDA 510(k) summary for CRYOcheck FVIII Inhibitor Kit, a quantitative kit for measuring functional Factor VIII inhibitor titer to aid management of hemophilia A using modified Nijmegen-Bethesda assay",
    "Indications for Use Summary": "For clinical laboratory use with a Factor VIII activity assay to perform a modified Nijmegen-Bethesda assay in 3.2% citrated human plasma, enabling determination of functional Factor VIII inhibitor titer to aid in the clinical management of congenital hemophilia A in individuals aged 2 years or older; for in vitro diagnostic use.",
    "fda_folder": "Hematology"
}